15-min delayed · Jul 28, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 1 firms covering Emergent Biosolutions Inc, 1 rate it Buy or better, 0 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets are tightly clustered, $12.00 to $12.00, so the covering firms are broadly aligned. The average target of $12.00 sits 64% above the current $7.30. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.35 next quarter toward $0.91 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS1 ratings
Strong Buy
Strong Buy00%
Buy1100%
Hold00%
Sell00%
Strong Sell00%
Based on 1 analysts giving stock ratings to Emergent Biosolutions Inc.
As of Jul, 1 of 1 firms rate EBS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
EBS EPS & revenue forecast
EPS · NEXT QUARTER
$0.35
Range $0.35 – $0.35 · 1 analysts · -67% YoY
Next period, 1 analysts expect Emergent Biosolutions Inc to earn $0.35 a share (range $0.35 – $0.35), versus $1.06 a year earlier. Full-year consensus is $0.95, growing to $0.91 the year after.
REVENUE · NEXT QUARTER
$209.0M
Range $203.0M – $215.0M · 1 analysts · -10% YoY
Revenue is expected to reach $209.0M (range $203.0M – $215.0M), -9.6% year-over-year. Full-year consensus is $733.0M, rising to $892.0M next year.
Top analysts covering Emergent Biosolutions Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on EBS.
#1
Raghuram Selvaraju
HC Wainwright & Co. · Rank #249
Buy
$12.00+64.4% to target
Overall win rate
37%
+ Follow
#2
RW
Robert Wasserman
Benchmark · Rank #259
Buy
$12.00+64.4% to target
Overall win rate
39%
+ Follow
#3
BF
Brandon Folkes
Rodman & Renshaw
Buy
$16.00+119.2% to target
Coverage
—
+ Follow
EBS stock forecast FAQ
What is EBS's average 12-month price target?+
The 1 analysts with a live target average $12.00 for Emergent Biosolutions Inc over the next 12 months, ranging from a $12.00 high to a $12.00 low.
Is EBS stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 1 analyst ratings, 1 are Buy or Strong Buy, 0 are Hold, and 0 are Sell or Strong Sell.
How many Wall Street analysts cover EBS?+
1 analysts have an active rating on Emergent Biosolutions Inc, and 1 firms carry a live 12-month price target.
Who is the most accurate analyst covering EBS?+
Among analysts who currently cover EBS, Raghuram Selvaraju of HC Wainwright & Co. has the strongest overall Quantellect track record (Rank #249). Their current call is Buy with a $12.00 target.
What is Emergent Biosolutions Inc's projected EPS for next quarter?+
The consensus estimate is $0.35 per share (range $0.35 – $0.35) across 1 analysts. Full-year EPS is projected at $0.95, rising to $0.91 the following year.
How much revenue is Emergent Biosolutions Inc expected to report next quarter?+
Consensus revenue is $209.0M (range $203.0M – $215.0M). Full-year revenue is projected at $733.0M, growing to $892.0M next year.
Have analysts been upgrading or downgrading EBS lately?+
As of Jul, 1 of 1 firms rate EBS a Buy (0 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their EBS calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
